Search clinical trials for: Manufactured Anti-BCMA CAR-T cells

Total 1316 results

Jian-Kun Hu

Recruiting

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

Metastases, Neoplasm | Neoplasm Seeding | Neoplasm, Stomach

China
Shanghai East Hospital
Bio4T2 LLC

Active, not recruiting

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Relapsed and/or Refractory Acute Lymphoblastic Leukemia | Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma

China
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
University College, London

Completed

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation (CARD)

CD19+ Malignancies: Relapse Post-allogeneic Transplant

United Kingdom
Shanghai Changzheng Hospital

Recruiting

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University

Recruiting

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

Immunotherapy

China
Memorial Sloan Kettering Cancer Center

Withdrawn

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Lymphoma | Lymphoma, B-Cell | Leukemia

United States
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for HCC Targeting GPC3

CAR-T Cell Immunotherapy | GPC3 Positive Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
National Taiwan University Hospital

Not yet recruiting

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

Relapsed/Refractory B-Cell Malignancies
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
Peking Union Medical College Hospital

Unknown

A Study of EXP039 Treatment in Subjects With r/r NHL Subjects

Non-Hodgkin's B-cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）

B-cell Acute Lymphoblastic Leukemia

China
Poseida Therapeutics, Inc.

Recruiting

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Nasopharyngeal Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Breast Cancer

China
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
Zhu Xiaofan

Recruiting

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

B Lymphoblastic Lymphoma | B Lymphocytic Leukemia

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

GD2 Positive Glioma | CAR-T Cell Immunotherapy

China
Hrain Biotechnology Co., Ltd.
Ruijin Hospital

Not yet recruiting

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Eutilex

Recruiting

To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

Advanced Hepatocellular Carcinoma

Korea, Republic of
National University Hospital, Singapore

Recruiting

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome | Refractory Leukemia

Singapore
National University Hospital, Singapore

Recruiting

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. (ALaCART)

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome

Singapore
The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University

Recruiting

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Immunotherapy

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Hepatocellular Carcinoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

CAR-T Cell Immunotherapy | EphA2 Positive Malignant Glioma

China
First Affiliated Hospital of Chengdu Medical College

Unknown

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (CARTEPC)

Gastric Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Esophageal Carcinoma | Hepatic Carcinoma

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
City of Hope Medical Center

Not yet recruiting

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

HIV-1

United States
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Central Nervous System Lymphoma

China
University of Pennsylvania

Completed

CART-19 for Multiple Myeloma

Multiple Myeloma

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States

Search clinical trials for: Manufactured Anti-BCMA CAR-T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations